Regeneron Pharmaceuticals Inc (BSP:REGN34)
R$ 89.25 1.25 (1.42%) Market Cap: 590.31 Bil Enterprise Value: 549.72 Bil PE Ratio: 24.59 PB Ratio: 3.63 GF Score: 86/100

Regeneron Pharmaceuticals Inc at Cowen Health Care Conference Transcript

Mar 11, 2019 / 03:20PM GMT
Yaron Benjamin Werber
Cowen and Company, LLC, Research Division - MD & Senior Biotechnology Analyst

Okay. Well, good afternoon, everybody or good late morning, and thank you so much for joining us for the 39th annual health care conference at Cowen. And it's a great pleasure to introduce Bob Landry, CFO; and Jay Markowitz, SVP of Portfolio Management for Regeneron.

Questions & Answers

Yaron Benjamin Werber
Cowen and Company, LLC, Research Division - MD & Senior Biotechnology Analyst

So we have, I think, a fairly aggressive agenda. So we want to talk about financial view for the company over time and the collaboration with Sanofi, and then, obviously, drilling into the pipeline as well. But I think, first, I think it's worthwhile taking a step back and talking about Regeneron broadly as a company and culturally and capability-wise and expertise-wise what makes Regeneron different. And the company was ranked #1 yet again in the biopharma survey. You're the #1 employer. And I know you're both newer to the Regeneron story that's been ongoing for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot